Evaxion A/S American Depositary Share (EVAX)
EVAX trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$2.76
-8.00% on the day
Market cap
$24.9M
Nano cap
Revenue · 2025
$7.5M
No prior year to compare
Net income · 2025
-$7.7M
-102.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1828253/000117184326001346/0001171843-26-001346-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | EVAX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Denmark |
| IPO year | 2021 |
| SEC CIK | 0001828253 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | G7 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $7.5M |
| Net income | -$7.7M |
| Operating income | Not in SEC XBRL data |
| Net margin | -102.4% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.3× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-10 |
| Latest annual report FORM 20-F | 20-F | 2026-03-05 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-10-02 |
Source: SEC EDGAR submissions feed, 358 recent filings. All filings on EDGAR.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CVM | Cel-Sci Corporation | $1.75 | -4.37% | $30.8M |
| ATYR | aTyr Pharma Inc. | $0.2011 | -6.38% | $19.7M |
| ELUT | Elutia Inc. | $0.7732 | -1.75% | $34.2M |
| ALGS | Aligos Therapeutics Inc. | $5.51 | -0.36% | $34.4M |
| MGX | Metagenomi Therapeutics Inc. | $0.9173 | -10.07% | $34.7M |
| GNTA | Genenta Science S.p.A. | $0.7220 | -4.99% | $34.8M |
| DYAI | Dyadic International Inc. | $0.4253 | +1.00% | $17.0M |
| JSPR | Jasper Therapeutics Inc. | $0.4956 | -10.70% | $16.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier